Andere Sprachen BioArctic AB

Aktien

A2H5GS

SE0010323311

BIOA B

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:33 18.04.2024			% 5 Tage	% 1. Jan.
193.8 ^SEK	-1.62%		-1.82%	-27.63%

01.04.	BioArctic und Eisai beantragen US FDA-Zulassung für Erhaltungsdosis des Alzheimer-Medikaments	MT
22.03.	BioArctic meldet Verzögerung der EU-Gesundheitsbehörde bei der Bewertung des Azlheimer-Medikaments	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioArctic publishes the Annual Report for 2023	18.04.
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB	16.04.
Nordic Shares Moved Upward Monday; Invisio Led Increases	15.04.
Nordic Stocks Rose Friday; BioArctic Series B Climbed Highest	12.04.
BioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm	10.04.
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	01.04.
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed	01.04.
BioArctic AB - Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	25.03.
Nordic Stocks Declined Friday; BioArctic Series B Took Biggest Hit	22.03.
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	22.03.
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	22.03.
Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease	19.03.
New data on lecanemab presented at the 2024 AD/PD™ congress	11.03.
BioArctic AB and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders	11.03.
BioArctic's partner Eisai presents updated sales simulation for Leqembi at its annual press conference	08.03.
BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference	07.03.
BioArctic AB - Latest data on lecanemab to be presented at the 2024 AD/PD congress	01.03.
Number of shares and votes in BioArctic AB (publ) as of February 29, 2024	29.02.
Latest data on lecanemab to be presented at the 2024 AD/PD™ congress	29.02.
BioArctic's CEO Gunilla Osswald Winner of The Arthur D. Little Nordic Life Science Award	22.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioArctic AB

Aktien

A2H5GS

SE0010323311

BIOA B

Andere Sprachen

Filter